An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

The use of Gilead’s Trodelvy and Merck’s Keytruda together could be practice-changing based on the results of a new study ...